English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Scavenger receptor class A, member 5 (SCARA5) is a member of the scavenger receptor family, and is involved in several types of human malignancy; however, its roles in osteosarcoma (OS) remain to be fully elucidated. Therefore, in the present study, the biological functions of SCARA5 in OS, and the potential underlying mechanisms were investigated. SCARA5 expression in OS tissues and cell lines was detected by reverse transcription‑quantitative polymerase chain reaction and western blot analysis. The effects of SCARA5 on the proliferation and migration/invasion ability of OS cells were determined by MTT and Transwell chamber assays, respectively. Expression levels of phosphorylated focal adhesion kinase (p‑FAK), FAK, p‑Src, Src, matrix metalloproteinase (MMP)2 and MMP9 were evaluated via western blot analysis. The results of the present study demonstrated that SCARA5 was expressed at low levels in OS tissues and cell lines. The overexpression of SCARA5 significantly inhibited the proliferation, colony formation and migration/invasion abilities of the OS cells. Furthermore, SCARA5 significantly decreased the expression levels of p‑FAK, MMP‑2 and MMP‑9 in the OS cells. Taken together, these data suggested that the overexpression of SCARA5 inhibits tumor proliferation and invasion in OS via suppression of the FAK signaling pathway. Thus, novel therapeutic strategies or drugs targeted at SCARA5 may offer potential for the treatment of OS.

Overexpression of SCARA5 inhibits tumor proliferation and invasion in osteosarcoma via suppression of the FAK signaling pathway